OMCLHIGH SIGNALFINANCIAL10-K

OMCL experienced a sharp decline in profitability and operating cash generation despite meaningful debt reduction and positioning around autonomous pharmacy infrastructure.

The substantial deterioration in net income alongside weakened operating cash flow signals potential execution challenges or market headwinds affecting the company's core medication management business. While the significant debt reduction demonstrates improved balance sheet management, the overall financial performance raises questions about near-term operational efficiency and margin pressures.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

OMCL's financial profile shows mixed signals with a concerning operational picture offset by balance sheet improvements. Profitability declined substantially while operating cash flow weakened meaningfully, suggesting core business challenges. However, the company strengthened its balance sheet by reducing total debt significantly from $140M to $50M, though this was partially offset by lower cash reserves dropping to $196.5M, indicating potential cash deployment for debt reduction or operational investments.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-83.6%
$12.5M→$2.1M

Net income declined 83.6% — review whether driven by operations, interest costs, or non-recurring items.

Total Debt
Balance Sheet
-64.3%
$140.0M→$50.0M

Debt reduced 64.3% — deleveraging strengthens balance sheet and reduces financial risk.

Cash & Equivalents
Balance Sheet
-46.8%
$369.2M→$196.5M

Cash declined 46.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Cash Flow
Cash Flow
-32.2%
$187.7M→$127.3M

Operating cash flow fell 32.2% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
-20%
$595.7M→$476.6M

Current liabilities reduced — improved short-term financial position and working capital health.

Current Assets
Balance Sheet
-16.6%
$815.5M→$680.1M

Current assets declined 16.6% — monitor working capital adequacy and short-term liquidity.

Total Liabilities
Balance Sheet
-15.4%
$877.6M→$742.9M

Liabilities reduced 15.4% — deleveraging improves balance sheet strength and financial flexibility.

Inventory
Balance Sheet
+13.8%
$88.7M→$100.9M

Inventory built 13.8% — monitor whether demand supports this build or if write-downs may follow.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
As of February 18, 2026, there were 45,435,918 shares of the registrant s common stock, $0.001 par value, outstanding.
BUSINESS Overview Omnicell, a leading healthcare technology provider focused on empowering autonomous medication management, is committed to solving the critical challenges inherent in medication management and elevating the role of clinicians within healthcare as an essential component of care delivery.
We are doing this with an industry-leading medication management infrastructure which includes storage and dispensing automation powered by an intelligence ecosystem.
Our comprehensive set of solutions provides the critical foundation for customers to realize the Autonomous Pharmacy, an industry-wide vision defined by pharmacy leaders for improving operational efficiencies and ultimately targeting zero-error medication management alongside 5 other outcomes laid out in the Autonomous Pharmacy framework.
Business Strategy In 2024, the United States spent $806 billion on prescription drugs, a 10.2% increase from 2023.
We believe there are significant challenges facing the practice of pharmacy today.
These challenges include, but are not limited to, budget constraints and acute workforce shortages, where 88% of hospitals report technician deficits and 92% lack sufficient sterile compounding expertise.
In addition, health systems face rising liability related to drug diversion, with a 61% increase in the average number of investigations per hospital since the beginning of 2023.
However, we believe that over time these significant challenges facing pharmacists will drive demand for increased automation, visibility, insights, and improved medication management outcomes that our solutions are designed to enable.
Furthermore, we believe a combination of dispensing automation and an intelligence ecosystem is needed in every care setting where medications are managed.
REMOVED
As of February 19, 2025, there were 46,759,414 shares of the registrant s common stock, $0.001 par value, outstanding.
BUSINESS Overview Omnicell, a leader in transforming the pharmacy and nursing care delivery model, is committed to solving the critical challenges inherent in medication management and elevating the role of clinicians within healthcare as an essential component of care delivery.
We are doing this with an industry-leading medication management infrastructure which includes robotics and smart devices, software workflows, expert services, and operational and optimization analytics.
This comprehensive set of solutions provides the critical foundation for customers to realize the Autonomous Pharmacy, an industry-wide vision defined by pharmacy leaders for improving operational efficiencies and ultimately targeting zero-error medication management.
Business Strategy In 2023, the United States spent $723 billion on prescription drugs, a 13.6% increase from 2022.
This was the largest annual spending increase in 20 years and impacted patients in virtually all settings of care.
We believe there are significant challenges facing the practice of pharmacy today including, but not limited to, budget constraints, increased healthcare worker turnover rates, labor shortages, drug shortages, drug diversion, manual and error-prone processes, complex compliance requirements, and limited inventory visibility.
Each of these challenges may lead to poor medication management outcomes including, but not limited to, medication errors, adverse drug events, lack of patient adherence, and medication waste.
However, we believe that over time these significant challenges to the practice of pharmacy will drive demand for increased automation, visibility, insights, and improved medication management outcomes that our solutions are designed to enable.
Furthermore, we believe a combination of robotics and smart devices, software workflows, expert services, and operational and optimization analytics is needed in every care setting where medications are managed.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →